CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) have been assigned a consensus recommendation of “Moderate Buy” from the six analysts that are currently covering the company, Marketbeat.com reports. Three analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $5.77.

Separately, HC Wainwright restated a “neutral” rating on shares of CytomX Therapeutics in a research note on Tuesday, January 7th.

CytomX Therapeutics Trading Down 3.6 %

Shares of CTMX opened at $0.80 on Friday. The company’s fifty day simple moving average is $0.97 and its 200 day simple moving average is $1.08. CytomX Therapeutics has a 1-year low of $0.75 and a 1-year high of $5.85. The company has a market cap of $62.32 million, a price-to-earnings ratio of 4.68 and a beta of 1.01.

Institutional Trading of CytomX Therapeutics

A number of hedge funds have recently modified their holdings of the stock. FMR LLC lifted its position in CytomX Therapeutics by 17.3% during the third quarter. FMR LLC now owns 284,307 shares of the biotechnology company’s stock worth $335,000 after acquiring an additional 41,949 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of CytomX Therapeutics by 4.4% during the third quarter. Geode Capital Management LLC now owns 803,531 shares of the biotechnology company’s stock worth $948,000 after purchasing an additional 34,032 shares during the period. Cubist Systematic Strategies LLC lifted its holdings in CytomX Therapeutics by 96.6% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 82,054 shares of the biotechnology company’s stock worth $100,000 after purchasing an additional 40,309 shares during the last quarter. US Bancorp DE bought a new stake in CytomX Therapeutics in the 3rd quarter valued at $40,000. Finally, Assenagon Asset Management S.A. grew its holdings in CytomX Therapeutics by 32.8% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,644,168 shares of the biotechnology company’s stock valued at $1,940,000 after buying an additional 405,669 shares in the last quarter. Institutional investors and hedge funds own 67.77% of the company’s stock.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.